Absci is trading up 5.02% at $9.53 on October 21, 2026, amid biotech-sector strength.
- Biotech sentiment has been supported by M&A activity and positive clinical-trial news; the biotech ETF was up 2.10% in the regular session.
- No fresh company-specific catalyst surfaced October 21. KeyBanc’s October 16 target increase to $20 from $16 is prior news, not clear evidence of the move’s cause.
- Absci’s next scheduled business update and Q3 results are November 12.